Mayne Pharma Group Limited (ASX:MYX)

United States Steel Revenue

Mayne Pharma Group had revenue of 213.05M AUD in the half year ending December 31, 2024, with 307.91% growth. This brings the company's revenue in the last twelve months to 413.53M, up 64.47% year-over-year. In the fiscal year ending June 30, 2024, Mayne Pharma Group had annual revenue of 388.40M with 111.56% growth.

• Revenue (ttm): 413.53M
• Revenue Growth: +64.47%
• P/S Ratio: 0.97
• Revenue / Employee: 427.64K
• Employees: 967
• Market Cap: 402.17M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2024	388.40M	204.81M	111.56%
Jun 30, 2023	183.59M	26.44M	16.82%
Jun 30, 2022	157.15M	-243.63M	-60.79%
Jun 30, 2021	400.78M	-56.20M	-12.30%
Jun 30, 2020	456.99M	-68.22M	-12.99%